Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer - Episode 4

Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer

,

The panel examines how resistance mutations influence the efficacy of subsequent treatment lines and delves into the process of selecting later-line therapies based on next-generation sequencing results.

EP. 1: Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer
EP. 2: First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance
EP. 3: Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway
Now Viewing
EP. 4: Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer
EP. 5: Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291
EP. 6: Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer
EP. 7: Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer
EP. 8: Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer